• IAC 2020 Virtual: Patterns of Antiretroviral Use and Immunologic Correlates at Study Entry in the REPRIEVE Trial - (08/04/20)
   
  
• IAC 2020 Virtual: Illicit Opioid Use After Changes in Opioids Prescribed for Chronic Pain Among People Living With and Without HIV - (08/01/20)
   
  
• IAC 2020 Virtual: Plenary: Casualties on the road to ending HIV: Context matters in addressing HIV disparities. From the very beginning of the 40-year HIV pandemic until today, HIV disparities have remained an intractable issue. - (08/01/20)
   
  
• IAC 2020 Virtual: Cabotegravir+Rilpivirine Long-Acting Injectable PrEP at IAC 2020 - (08/01/20)
   
  
• Aging/HIV AIDS United Policy/Advocacy Paper - (07/31/20)
   
  
More HIV Articles...
 

• UNAIDS Press release - COVID-19 could affect the availability and cost of antiretroviral medicines, but the risks can be mitigated - (06/25/20)
   
  
• UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - (06/24/20)
   
  
• Coronavirus puts drug repurposing on the fast track - (03/02/20)
   
  
• FDA Expands Coronavirus Testing in the United States - (03/02/20)
   
  
More News Updates Articles...
 

• HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - -
   
  
• EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany-
   
  
• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• Research Needs Editorial - Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia
  About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus - (07/30/20)
   
  
More Hep C Articles...
 

• Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/11/20)
   
  
• VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial - press release - (04/20/20)
   
  
• Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection - (04/20/20)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.